Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models.
We evaluated the antitumor effect of combined therapy with tegafur/uracil (UFT) plus leucovorin (LV) (UFT/LV) and protein-bound polysaccharide, PSK, in three mouse models of transplantable tumors. UFT/LV showed antitumor effect against Meth A sarcoma, and the antitumor effect was enhanced when PSK given concomitantly. UFT/LV showed antitumor effect to Lewis lung carcinoma and PSK alone also showed antitumor effect at high dose, but a combination of UFT/LV and PSK resulted in no enhanced antitumor effect. Colon 26 carcinoma was weakly responsive to UFT/LV, and no enhancement of antitumor effect was found even PSK was used in combination. In conclusion, while the effect of PSK varies depending on tumor, combined use of UFT/LV and PSK may be expected to augment the antitumor effect.
Katoh
Ryoji
R
Department of Surgery, Toho University Sakura Medical Center, Sakura-shi, Chiba, Japan. ryochan@sakura.med.toho-u.ac.jp
Ooshiro
Mitsuru
M
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D002955:Leucovorin / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011509:Proteoglycans / Q000494:pharmacology* / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy; D005641:Tegafur / Q000494:pharmacology* / Q000627:therapeutic use; D014498:Uracil / Q000494:pharmacology* / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D011509:Proteoglycans; D005641:Tegafur; C010770:polysaccharide-K; D014498:Uracil; D002955:Leucovorin